Sen. Ron Johnson (R-Wisc.) announced Tuesday that he will begin an investigation into how the FDA processes approval applications for biologic therapies to treat Duchenne muscular dystrophy (DMD) and other rare, life-threatening disorders. The investigation will focus on FDA rejections of drugs for these rare diseases. The report comes from MedPage Today. The article does not provide other specific statistics or details about the progress of the investigation.